Menotropin - Ferring

Drug Profile

Menotropin - Ferring

Alternative Names: HMG; HP-hMG; Human menopausal gonadotrophin; Menogon; Menopur; Menotrophin; Menotropins; Merapur; Meropur; Repronex

Latest Information Update: 20 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Infertility therapies; Menotropins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Female infertility; Polycystic ovary syndrome

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 20 Jul 2016 Launched for Female infertility in South Korea (SC) before July 2016
  • 12 Mar 2014 Ferring completes a phase III trial comparing 450 and 600IU daily doses of menotropin in Female infertility in Canada (NCT00971152)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top